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We examined how systemic blockade of type 1 angiotensin (AT1-) receptors affects reﬂex
control of the circulation and the kidney. In conscious rabbits, the effects of candesar-
tan on responses of systemic and renal hemodynamics and renal excretory function to
acute hypoxia, mild hemorrhage, and plasma volume expansion were tested. Candesar-
tan reduced resting mean arterial pressure (MAP, −8± 2%) without signiﬁcantly altering
cardiac output (CO), increased renal blood ﬂow (RBF, +38± 9%) and reduced renal vas-
cular resistance (RVR, −32± 6%). Glomerular ﬁltration rate (GFR) was not signiﬁcantly
altered but sodium excretion (UNa V) increased fourfold. After vehicle treatment, hypoxia+
(10% inspired O2 for 30min) did not signiﬁcantly alter MAP or CO, but reduced heart
rate (HR, −17± 6%), increased RVR (+33± 16%) and reduced GFR (−46± 16%) and
UNa V (+ −41± 17%). Candesartan did not signiﬁcantly alter these responses. After vehicle
treatment, plasma volume expansion increased CO (+35± 7%), reduced total peripheral
resistance (TPR, −26± 5%), increased RBF (+62± 23%) and reduced RVR (−32± 9%),
but did not signiﬁcantly alter MAP or HR. It also increased UNa V (803+ ± 184%) yet reduced
GFR (−47± 9%). Candesartan did not signiﬁcantly alter these responses. After vehicle
treatment, mild hemorrhage did not signiﬁcantly alter MAP but increased HR (+16± 3%),
reduced CO (−16± 4%) and RBF (−18± 6%), increased TPR (+18± 4%) and tended to
increase RVR (+18± 9%, P = 0.1), but had little effect on GFR or UNa V. But after can-+
desartan treatment MAP fell during hemorrhage (−19± 1%), while neither TPR nor RVR
increased, and GFR (−64± 18%) and UNa V (−83± 10%) fell. AT+ 1-receptor activation sup-
ports MAP and GFR during hypovolemia. But AT1-receptors appear to play little role in
the renal vasoconstriction, hypoﬁltration, and antinatriuresis accompanying hypoxia, or the
systemic and renal vasodilatation and natriuresis accompanying plasma volume expansion.
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INTRODUCTION
Drugs that interfere with the function of the renin-angiotensin
system (RAS) are the most commonly prescribed class of agents
for the treatment of hypertension (Muntner et al., 2009; Vitry
and Lai, 2009). These include inhibitors of angiotensin converting
enzyme, angiotensin II type 1 (AT1) receptor antagonists, and the
more recently introduced direct renin inhibitors (Riccioni et al.,
2010). One of the hallmarks of these agents is the relative lack of
adverse effects such as postural hypotension (Hajjar, 2005) and
salt and water retention (Sharma, 2004), which are seen with some
other antihypertensive agents.
It is generally accepted that antihypertensive agents that target
the RAS system do not impede reﬂex control of the circulation to
the same extent as many other therapeutic modalities (Fridman
et al., 1999). This property, in turn, is believed to contribute to their
tolerability (Hajjar, 2005). On the other hand, an ability to impede
pro-hypertensive circulatory and renal responses to stimuli such
as hypoxia and hypovolemia, or to enhance antihypertensive
compensatory responses to hypervolemia, could potentially con-
tribute to their antihypertensive efﬁcacy. Yet there is a general lack
of consensus regarding the effects of AT1-receptor antagonists on
reﬂex control of the circulation and the kidney.
The effects of angiotensin receptor antagonists on the blood
pressure response to hemorrhage have been studied extensively in
multiple species. For example, blockade of angiotensin II recep-
tors reduced mean arterial pressure (MAP) after hemorrhage in
conscious dogs (Spielman et al., 1975). It also blunted the recov-
ery of MAP after hemorrhage in conscious rats, without altering
the acute response of MAP to blood loss (Ponchon and Elghozi,
1997). Other studies have demonstrated an augmented depressor
response to hemorrhage after blockade of central AT1-receptors in
conscious rats (Lee et al., 1995) or systemic AT1-receptor blockade
in conscious dogs (Francis et al., 2004), or an early occurrence of
the decompensatory phase of the response to progressive hypo-
volemia in conscious sheep after central AT1-receptor blockade
(Mathai et al., 1997). Yet in only one of these studies was cardiac
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output (CO) measured (Francis et al., 2004) and in none was
renal blood ﬂow (RBF) measured. The one study are aware of, in
which the effects of RAS inhibition on responses of RBF to hem-
orrhage were assessed, examined the effects of combined blockade
of angiotensin converting enzyme and vasopressin V1-receptors
(Courneya and Korner, 1991). Thus, the speciﬁc roles of AT1-
receptors in responses of renal and systemic vascular resistance
to hemorrhage remain largely unexplored. The effects of sys-
temic angiotensin receptor blockade on hemodynamic and renal
responses to other cardiovascular reﬂexes, such as those evoked
by hypoxemia, have been studied in anesthetized animals (Ney-
lon et al., 1996). But because such responses are likely affected by
anesthesia, studies in conscious animals are warranted.
In the current study we tested the hypothesis that AT1-receptor
blockade affects responses of the circulation and kidney to circu-
latory stressors in a manner that would be expected to contribute
toward the antihypertensive efﬁcacy of this therapeutic modality.
Therefore, we aimed to examine the impact of candesartan on
hemodynamic and renal responses to hemorrhage, hypoxia, and
plasma volume expansion, in chronically instrumented conscious
rabbits.
MATERIALS AND METHODS
ANIMALS
Male New ZealandWhite rabbits (n = 7, 3.22± 0.13 kg at the time
of their ﬁrst experimental observations) were studied, accord-
ing to the Australian Code of Practice for the Care and Use of
Animals for Scientiﬁc Purposes. The experimental protocol was
approved in advance by the Animal Ethics Committee of the
School of Biomedical Sciences, Monash University. After recovery
frompreliminary surgery, each rabbit was studied on four separate
experimental days at 1 week intervals. During these experiments
we examined responses to hypoxia and plasma volume expansion
(after administration of candesartan or its vehicle) or hemorrhage
(after candesartan or its vehicle). The order of the treatments was
randomized.
PRELIMINARY SURGERY
Major procedures
Each rabbit underwent two surgical procedures. For both, anesthe-
sia was induced with i.v. propofol (10mg/kg; Diprivan, ICI, VIC,
Australia), and following endotracheal intubation, maintained
with isoﬂurane (1–4% w/v; Isoﬂo, Abbott Australasia, Kurnell,
NSW, Australia). The ﬁrst procedure involved implantation of a
transit-time ultrasound ﬂow probe (type 6SB, Transonic Systems,
Ithaca, USA) around the ascending aorta via a left thoracotomy,
for later measurement of CO (Shweta et al., 1999). At the second
operation, performed 2weeks after the ﬁrst, a transit-time ﬂow
probe (type 2SB, Transonic Systems, Ithaca, USA) was implanted
around the left renal artery for measurement of RBF (Shweta
et al., 1999). The connectors of the ﬂow probes were tunneled
subcutaneously for later retrieval on the day of the experiment.
Experimental studies commenced at least 2 weeks after the second
surgical procedure.
Minor procedures on study days
These were performed under local analgesia (1% w/v ligno-
caine,Xylocaine,AstraZeneca,NSW,Australia). Catheters (Optiva,
Johnson & Johnson, NSW, Australia) were placed in the marginal
ear vein for infusion of drugs, and central ear artery for mea-
surement of arterial pressure. The ﬂow probe connectors were
retrieved from their subcutaneous positions. The rabbit was then
brieﬂy anesthetized (propofol, 10mg/kg, i.v.) to allow insertion
of a bladder catheter (Rusch Symcath, 2.7mm pediatric, Teleﬂex
Medical, Kamunting, Malaysia). All rabbits regained conscious-
ness, as assessed by the righting reﬂex, within 5min of placement
of the catheter. [3H]-inulin (Perkin Elmer,Rowville,Australia)was
then administered as a bolus of 10μCi in 0.5ml and an infusion
of 34.4 nCi/kg/min. The [3H]-inulin infusion, which continued
for the day’s experimental protocol (see below), was administered
in an isotonic solution of glucose (4% w/v) and NaCl (0.18%
w/v) delivered intravenously at a rate of 0.1ml/kg/min. This ﬂuid
regimen, which is similar to that which we have used previously
(Tomoda et al., 1996; Norman et al., 2001), induces some degree
of diuresis but not natriuresis. An equilibration period of 60min
was allowed, from administration of the [3H]-inulin bolus, before
the experimental protocol began.
EXPERIMENTAL PROTOCOLS
Each experiment consisted of a series of 20min clearance peri-
ods, during which urine was collected. At the mid-point of each
clearance period, a 0.5-ml sample of arterial blood was collected
to facilitate renal clearance measurements. After an initial control
clearance period, either candesartan (10μg/kg+ 10μg/kg/h) or
its vehicle (1ml/kg+ 1ml/kg/h of 0.9% w/v NaCl) was adminis-
tered. A second 20min clearance period then commenced 30min
after treatment with candesartan or its vehicle began.
On each experimental day, we then tested responses to either
hypoxia and plasma volume expansion, or hemorrhage. The
hypoxia protocol comprised three 30min periods, during which
the rabbit breathed room air, a mixture of 10% oxygen with
4% carbon dioxide, and then room air again. Carbon dioxide
was added to the inspired gas mixture to prevent development
of hypocapnia during hypoxia (Blake et al., 1994). Gas mixtures
were delivered at a rate of 2 l/min into a specially designed rab-
bit holding box constructed from plastic material so as to be
air-tight. Renal clearance measurements were obtained over the
ﬁnal 20min of each of the three 30min experimental periods. An
additional 0.5ml sample of arterial bloodwas collected at themid-
point of each of these clearance periods, for blood gas analysis.
After a further 30min recovery period, responses to plasma vol-
ume expansion were then examined over a series of ﬁve clearance
periods. After a control period, a polygeline/electrolyte solution
(Gelofusine, B. Braun Pty Ltd., Bella Vista, NSW, Australia) was
administered intravenously at a rate of 1ml/kg/min for 30min.
Upon completion of the infusion, a series of four consecutive
20min clearance periods commenced. On separate study days,
responses to hemorrhage were examined after administration of
candesartan or its vehicle. Responses to progressive hemorrhage
and re-infusion of shed blood were examined over a series of four
experimental periods. After a control period, 6ml/kg blood was
removed via the ear artery, over a 5-min period. Fiveminutes later,
a second clearance period commenced. A further 6ml/kg blood
was then removed over a 5-min period, and 5min later a third
clearance period commenced. The shed blood was then returned
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to the rabbit intravenously over a 10-min period. Tenminute after
completing blood infusion, a fourth clearance period commenced.
At the end of each study day we tested responses to an intra-
venous bolus of angiotensin II (100 ng/kg). The effectiveness of
candesartan was conﬁrmed by the absence of a pressor response to
angiotensin II after candesartan treatment.After vehicle treatment,
angiotensin II increasedMAPby approximately 27± 4mmHg,but
only by 3± 2mmHg after candesartan treatment.
MEASUREMENTS
Arterial pressure was measured via an ear artery catheter con-
nected to a pressure transducer (Cobe, Arvada, CO, USA) and
bridge ampliﬁer (Model QA1; Scientiﬁc Concepts, Mount Waver-
ley, VIC, Australia). The transit-time ultrasound ﬂow probes were
connected to a compatible ﬂowmeter (Model T206; Transonic Sys-
tems Inc.). Values of MAP, heart rate (HR, triggered by the arterial
pressure pulse), CO, and RBF were digitized as 2 s averages (Guild
et al., 2002). Total peripheral resistance (TPR)was calculated as the
quotient of MAP and CO, while renal vascular resistance (RVR)
was calculated as the quotient of MAP and RBF. Vena caval pres-
sure increases by only∼3mmHgduring plasma volume expansion
(Shweta et al., 1999) and likely falls by only∼2mmHg duringmild
hemorrhage (Ludbrook and Graham, 1984). Thus, errors due to
the absence of venous pressure in our calculations of TPR andRVR
are likely small. Blood gas analysis was performed on 0.5ml blood
samples using an ABL 700 series blood gas analyzer (Radiometer
Copenhagen). Glomerular ﬁltration rate (GFR) was measured as
the clearance of [3H]-inulin. Sodium concentrations in plasma
and urine were determined using a Synchron CX5 Clinical System
(Beckman–Coulter).
STATISTICS
Values were averaged over each clearance period and are expressed
as mean± SEM. Hypothesis testing was performed using the soft-
ware package SYSTAT (Version 10; SPSS, Chicago, IL, USA). Two
sided P≤ 0.05 was considered statistically signiﬁcant. Paired t -
tests were used to test for acute responses to candesartan or its
vehicle, examined over the ﬁrst two clearance periods of each
study day, or for other comparisons between successive experi-
mental periods. Because responses to candesartan and its vehicle
were determined twice in each rabbit, analysis of these data was
performed using the within-rabbit mean values for each variable.
Responses to hypoxia, plasma volume expansion, and hemorrhage
were then examined using two-way repeated measures analysis
of variance (Ludbrook, 1994). The main effect of the categori-
cal variable “time” tested whether, independent of pre-treatment
(candesartan or its vehicle), the various experimental maneuvers
altered the level of each variable. The main effect of the categori-
cal variable “treatment” tested whether, independent of time, the
levels of each variable differed after treatment with candesartan
compared with its vehicle. The “treatment X time” interaction
term tested whether candesartan treatment altered responses to
each maneuver.
RESULTS
All seven rabbits completed the entire experimental protocol.
However, in three rabbits the renal artery ﬂow probe was dysfunc-
tional. Consequently, n = 7 for all observations except for RBF, for
which n = 4.
ACUTE EFFECTS OF CANDESARTAN
Administration of candesartan induced a fall in MAP
(−8± 2mmHg) and increased HR (+14± 5 beats/min) and RBF
(+38± 9%), but no signiﬁcant change in CO was observed. RVR
fell by −32± 6%. GFR was not signiﬁcantly altered by candesar-
tan treatment, but sodium excretion and the fractional excre-
tion of sodium both increased more than fourfold. The vehicle
for candesartan did not signiﬁcantly affect any of the measured
hemodynamic or renal variables (Table 1).
RESPONSES TO HYPOXIA
After vehicle treatment, exposure to the hypoxic gas mixture
reduced arterial PO2 (by −66± 8mmHg) and hemoglobin sat-
uration (from 100±<1 to 64± 5%) and increased PCO2 (by
Table 1 | Responses of hemodynamic, and renal function variables to candesartan, and its vehicle.
Variable Vehicle Candesartan
Before After P Before After P
MAP (mmHg) 97±1 97±1 0.95 95±3 87±2 0.01
HR (beats/min) 241±10 241±9 0.93 246±8 260±10 0.02
CO (ml/min) 444±31 450±30 0.59 456±35 459±48 0.88
TPR (mmHg/mlmin) 0.23±0.02 0.23±0.02 0.59 0.22±0.02 0.20±0.02 0.16
RBF (ml/min) 44.1±3.9 40.9±5.5 0.31 44.0±4.7 61.3±8.5 0.04
RVR (mmHg/mlmin) 2.30±0.18 2.54±0.31 0.35 2.16±0.17 1.49±0.20 0.01
GFR (ml/min) 18.0±3.2 17.9±4.4 0.98 16.6±3.8 16.6±1.9 0.99
UNa+V (μmol/min) 19.6±6.6 13.8±3.1 0.42 24.1±9.9 101.0±32.9 0.03
FENa+ (%) 0.7±0.2 0.7±0.2 0.84 0.9±0.3 4.2±1.3 0.02
Values represent mean±SEM of seven observations, except for RBF and RVR, for which n=4 because the renal artery ﬂow probe was not operational in three
rabbits. MAP, mean arterial pressure; HR, heart rate; CO, cardiac output; RBF, renal blood ﬂow; RVR, renal vascular resistance; GFR, glomerular ﬁltration rate; UNa+V,
sodium excretion; FENa+, the fractional excretion of sodium. P values were generated from paired t-tests.
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10± 3mmHg) and tended to reduce arterial pH (by −0.10± 0.05
units). During the recovery period after exposure to the hypoxic
gas mixture, these variables returned to their control level.
Responses of blood gas variables to the hypoxic gas mixture after
candesartan treatment were indistinguishable from those after
vehicle treatment (Figure 1).
After vehicle treatment, hypoxia did not signiﬁcantly alter
MAP, CO, or TPR, but reduced HR (by −44± 16 beats/min) and
tended to reduce RBF (by −21± 8%, P= 0.08) and increase RVR
(by 33± 16%). Although candesartan treatment altered baseline
levels of MAP, RBF, and RVR, it did not signiﬁcantly alter the
hemodynamic responses to hypoxia (Figure 2).
FIGURE 1 | Arterial blood gases before, during and after hypoxia in
conscious rabbits treated with candesartan or its vehicle. PO2, the
partial pressure of oxygen; PCO2, the partial pressure of carbon dioxide; C,
control; H, hypoxia; R, recovery. P values represent the outcomes of
two-way repeated measures analysis of variance, indicating signiﬁcant
changes in arterial PO2, hemoglobin saturation, and PCO2 in response to
hypoxia.
After vehicle treatment, hypoxia tended to reduce GFR (by
−46± 16%, P = 0.06) and sodium excretion (by −41± 17%,
P = 0.06). Similar reductions in GFR and sodium excretion
were observed during hypoxia after candesartan treatment.
Thus, although candesartan altered the baseline levels of these
variables, it had little impact on their responses to hypoxia
(Figure 3).
RESPONSES TO PLASMA VOLUME EXPANSION
After vehicle treatment, infusion of the polygeline/electrolyte solu-
tion reduced hematocrit from 40.0± 0.6 to 28.7± 0.7%, corre-
sponding to a nominal plasma volume expansion of 66± 3%
and total blood volume expansion of 40± 2%. Hematocrit rose
slightly across the subsequent 80min, but always remained below
its control level. Hematocrit was slightly greater after treatment
with candesartan than vehicle (3.2± 1.2% when averaged over all
ﬁve clearance periods). However, the response to the infusion was
indistinguishable after candesartan treatment comparedwith after
vehicle treatment (Figure 4).
Plasma volume expansion was accompanied by increased CO
(+35± 7% during the ﬁrst clearance period after infusion of
polygeline/electrolyte solution) and reduced TPR (−26± 5%),
increased RBF (+62± 23%) and reduced RVR (−32± 9%), but
little change in MAP or HR (Figure 5). There were also increases
in sodium excretion (803± 184%) and the fractional excretion
of sodium (from 1.04± 0.37 to 17.83± 6.74%), and a decrease
FIGURE 2 | Responses of hemodynamic variables to hypoxia in
conscious rabbits treated with candesartan or its vehicle. MAP, mean
arterial pressure; HR, heart rate; CO, cardiac output; RBF, renal blood ﬂow;
TPR, total peripheral resistance; RVR, renal vascular resistance; C, control;
H, hypoxia; R, recovery. P values for the outcomes of two-way repeated
measures analysis of variance are shown inTable 2. These indicate
signiﬁcant effects of candesartan on MAP, RBF, TPR, and RVR, and a
signiﬁcant effect of hypoxia on HR. However, candesartan did not
signiﬁcantly affect responses to hypoxia.
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FIGURE 3 | Responses of renal excretory variables to hypoxia in
conscious rabbits treated with candesartan or its vehicle. GFR,
glomerular ﬁltration rate, UNa+V, sodium excretion; FENa+, fractional sodium
excretion; C, control; H, hypoxia; R, recovery. P values for the outcomes of
two-way repeated measures analysis of variance are shown inTable 2.
These indicate signiﬁcant effects of candesartan on UNa+V and FENa+ and a
signiﬁcant effect of hypoxia on GFR. However, candesartan did not
signiﬁcantly affect responses to hypoxia.
in GFR (−47± 9%; Figure 6). Hemodynamic and excretory
responses to plasma volume expansion were not signiﬁcantly
altered by candesartan treatment (Figures 5 and 6).
RESPONSES TO MILD HEMORRHAGE
After vehicle treatment, mild hemorrhage was accompanied
by little change in MAP (−2± 2mmHg after removal of
12ml/kg blood) but increasedHR (40± 6 beats/min), reducedCO
(−16± 4%) and RBF (−18± 6%), increased TPR (18± 4%) and
a tendency for increased RVR (18± 9%, P = 0.1). After candesar-
tan treatment,MAP fell during hemorrhage (−14± 1mmHg) and
FIGURE 4 | Responses of hematocrit to plasma volume expansion in
conscious rabbits treated with candesartan or its vehicle. C= control,
1, 2, 3, and 4 refer to the consecutive 20min clearance periods after plasma
volume expansion. P values are the outcomes of two-way repeated
measures analysis of variance. These indicate signiﬁcant effects of
candesartan and plasma volume expansion on hematocrit, but no
signiﬁcant effect of candesartan on the response of hematocrit to plasma
volume expansion.
FIGURE 5 | Responses of hemodynamic variables to plasma volume
expansion in conscious rabbits treated with candesartan or its vehicle.
MAP, mean arterial pressure; HR, heart rate; CO, cardiac output; RBF, renal
blood ﬂow; TPR, total peripheral resistance; RVR, renal vascular resistance.
C= control, 1, 2, 3, and 4 refer to the consecutive 20min clearance periods
after plasma volume expansion. P values for the outcomes of two-way
repeated measures analysis of variance are shown inTable 2. These
indicate signiﬁcant effects of candesartan on RBF and RVR and signiﬁcant
changes in CO, RBF, TPR, and RVR in response to plasma volume
expansion. However, there were no signiﬁcant effects of candesartan on
the responses of these variables to plasma volume expansion.
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FIGURE 6 | Responses of renal excretory variables to plasma volume
expansion in conscious rabbits treated with candesartan or its vehicle.
GFR, glomerular ﬁltration rate; UNa+V, sodium excretion; FENa+, fractional
sodium excretion. C= control, 1, 2, 3, and 4 refer to the consecutive 20min
clearance periods after plasma volume expansion. P values for the
outcomes of two-way repeated measures analysis of variance are shown in
Table 2. These indicate signiﬁcant changes in GFR, UNa+V, and FENa+ in
response to plasma volume expansion. However, there were no signiﬁcant
effects of candesartan on the responses of these variables to plasma
volume expansion.
the increases in TPR and RVR seen after vehicle treatment were
largely absent (Figure 7).
After vehicle treatment, hemorrhage was not accompanied
by signiﬁcant changes in GFR or sodium excretion. However,
the fractional excretion of sodium was consistently reduced,
from 1.63± 0.79% under control conditions to 0.46± 0.11%
after removal of 12ml/kg blood. In contrast, GFR (−64± 18%),
sodium excretion (−83± 10%), and the fractional excretion of
sodium (from 1.63± 0.33 to 0.71± 0.10%) fell during hemor-
rhage after candesartan treatment (Figure 8).
FIGURE 7 | Responses of hemodynamic variables to progressive
hemorrhage in conscious rabbits treated with candesartan or its
vehicle. MAP, mean arterial pressure; HR, heart rate; CO, cardiac output;
RBF, renal blood ﬂow; TPR, total peripheral resistance; RVR, renal vascular
resistance. H1=6ml/kg blood loss; H2=12ml/kg blood loss. P values for
the outcomes of repeated measures analysis of variance are shown in
Table 2. These indicate signiﬁcant effects of candesartan on MAP, RBF, and
RVR, signiﬁcant effects of hemorrhage on MAP, HR, CO, andTPR, and
signiﬁcant effects of candesartan on the responses of MAP and CO to
hemorrhage.
DISCUSSION
Our ﬁndings support a role for the RAS, through activation of
AT1-receptors, in supporting arterial pressure and glomerular ﬁl-
tration in the face of acute blood loss. But the RAS appears to
play little role in mediating the renal vasoconstriction, hypoﬁl-
tration, and antinatriuresis that accompanies hypoxia, or the sys-
temic and renal vasodilatation and natriuresis that accompanies
plasma volume expansion. Thus, while the ability of AT1-receptor
antagonists to blunt compensatory responses to hypovolemia may
contribute toward their antihypertensive efﬁcacy, our ﬁndings do
not support the notion that these agents acutely blunt the pro-
hypertensive responses to hypoxia or augment the compensatory
antihypertensive responses to hypervolemia.
In conscious, normotensive rabbits, candesartan administra-
tion acutely reduced MAP. We also observed an increase in RBF
(and reduction in RVR) and increased sodium excretion mainly
mediated by inhibition of tubular sodium reabsorption. The
ability of AT1-receptor antagonists like candesartan to enhance
sodium excretion, despite the fact that they reduce MAP, is crit-
ical to their longer-term efﬁcacy. That is, they chronically shift
the pressure natriuresis relationship to allow excretion of the daily
sodium load in the face of chronically lowered arterial pressure.
This is one of the desirable actions of an “ideal antihypertensive
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FIGURE 8 | Responses of renal excretory variables to progressive
hemorrhage in conscious rabbits treated with candesartan or its
vehicle. GFR, glomerular ﬁltration rate; UNa+V, sodium excretion; FENa+,
fractional sodium excretion. H1=6ml/kg blood loss; H2=12ml/kg blood
loss. P values for the outcomes of two-way repeated measures analysis of
variance are shown inTable 2. These failed to detect signiﬁcant effects of
candesartan or hemorrhage on GFR, UNa+V, and FENa+.
agent”(Evans et al., 2005a,b). Another desirable actionwould be to
modulate cardiovascular reﬂexes in a way that promotes the low-
ering of arterial pressure. Such effects could include the blunting
of responses to sympatho-excitatory stimuli such as activation of
arterial chemoreﬂexes as occurs in patientswith sleep apnea (Prab-
hakar and Kumar, 2010). Moreover, promotion of natriuresis in
response to increased plasma volume and/or enhancement of the
depressor response to reductions in blood volume could also be
desirable actions of an ideal antihypertensive agent. We assessed
the degree to which the AT1-receptor antagonist candesartan
fulﬁlls these criteria.
Hypoxia elicits a complex cardiovascular response, mediated
partly through activation of arterial chemoreceptors (Prabhakar
and Kumar, 2010) and partly through locally mediated changes
in vascular tone (Prabhakar and Kumar, 2010). Local hypoxia
induces vasodilatation in a range of vascular beds including skele-
tal muscle (Chalmers et al., 1966). But sympathetic vasomotor
drive is increased due to chemoreceptor activation, which medi-
ates vasoconstriction (Chalmers et al., 1965) that is particularly
prominent in the kidney (Malpas and Evans, 1998). In conscious
rabbits these competing inﬂuences often result in little or no
change in MAP, CO, or TPR during hypoxia, as in the current
study. However, there was a strong tendency for increased RVR.
Furthermore, the presence of pre-glomerular vasoconstrictionwas
supported by the ﬁnding of reduced GFR during hypoxia. The
renal effects of hypoxia are abolished by prior renal denervation
(Malpas and Evans, 1998; Leonard et al., 2001), indicating that
they are dependent upon activation of renal sympathetic nerve
activity. The renal sympathetic nerves mediate renal renin release
(Burke et al., 2007), which could contribute to the renal effects of
hypoxia. Indeed, hypoxia has been shown to increase plasma renin
activity in multiple species (Tufﬂey et al., 1970; Heyes et al., 1982),
including rabbits (Malpas and Evans, 1998; Evans et al., 2007).
The resultant increase in circulating angiotensin II could mod-
ulate the response to hypoxia at multiple sites, including within
the kidney itself (Dibona and Sawin, 2003; Le Fevre et al., 2003;
Rajapakse et al., 2005), the carotid body (Leung et al., 2003; Li et al.,
2006), and the neural pathways subserving the arterial chemoreﬂex
(Gaudet et al., 1997). Yet we found little impact of AT1-receptor
blockade on systemic and renal hemodynamic, and renal excre-
tory responses, to hypoxia. Our ﬁndings are consistent with those
of previous studies performed in anesthetized animals (Neylon
et al., 1996). In the case of severe hypoxia, which often produces
hypotension, the RAS appears to play some role in maintenance
of renal vascular tone (Liang and Gavras, 1978). Nevertheless, our
current ﬁndings provide deﬁnitive evidence that, in the absence
of confounding effects of hypotension as is often observed in rats
during hypoxia (Neylon et al., 1996), there is little role of the
RAS in the systemic hemodynamic and renal responses to acute
hypoxia.
More than 3% of the adult population experience sleep apnea
(Bixler et al., 1998), which results in chronic intermittent hypoxia
(Budhiraja et al., 2010). Sleep apnea is a major risk factor for
hypertension and cardiovascular disease (Budhiraja et al., 2010).
Chronic intermittent activation of the sympathetic nervous system
(SNS) in subjects with sleep apnea leads to chronically increased
sympathetic vasomotor drive which in turn promotes the devel-
opment of hypertension (Prabhakar andKumar, 2010). Activation
of the RAS, which has been observed in patients with sleep apnea
(Moller et al., 2003), may also contribute to the development of
hypertension. Indeed, in experimental animals, chronic blockade
of AT1-receptors can blunt the development of hypertension in
response to chronic intermittent hypoxia (Fletcher et al., 2002).
Furthermore, a recent human study demonstrated that losartan
can abolish the sustained increase in arterial pressure observed
after a 6-h bout of intermittent hypoxia (Foster et al., 2010). Thus,
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AT1-receptor antagonists appear able to counter many of the pro-
hypertensive consequences of sleep apnea. Adults and children
with sleep disordered breathing tend to have increased noctur-
nal sodium excretion, believed to be mediated chieﬂy through
pressure natriuresis (Warley and Stradling, 1988; Kaditis et al.,
2010). Activation of the SNS, and possibly also the RAS, dur-
ing hypoxia might be expected to limit this pressure natriure-
sis, and so contribute to the pro-hypertensive effects of sleep
apnea. Thus, a desirable property of an antihypertensive phar-
macotherapy for patients with sleep apnea would be to blunt the
acute sympatho-excitatory effects of hypoxia and/or reduce its
inﬂuence on renal function. Our current ﬁndings suggest that
the AT1-receptor antagonist candesartan does not possess these
actions.
Another desirable property of an antihypertensive agent would
be to promote salt and water excretion in the face of expansion of
either extracellular ﬂuid volume or plasma volume. When given
acutely, AT1-receptor antagonists enhance the diuretic and natri-
uretic response to extracellular ﬂuid volume expansion (Andersen
et al., 2002). But the natriuretic response to extracellular ﬂuid vol-
ume expansion is dominated by the associated reduction in plasma
colloid osmotic pressure (Cowley and Skelton, 1991), which is
likely to be less evident when plasma volume is expanded by
administration of a colloidal solution as in the current study.
We are aware of no previous studies that have investigated the
impact of AT1-receptor blockade on responses to plasma volume
expansion. Plasma volume expansion was accompanied by little
change in MAP but increased CO and reduced TPR. RBF and
sodium excretion increased yet GFR was reduced. None of these
effects were signiﬁcantly altered by prior candesartan treatment,
indicating little role for AT1-receptors in mediating natriuretic
responses to plasma volume expansion. These observations and
conclusions concord with those from previous studies indicat-
ing a pivotal role of cardiac baroreceptor mediated inhibition of
renal sympathetic vasomotor drive in the natriuretic response to
plasma volume expansion (Morita andVatner, 1985; Badoer et al.,
1998). Thus, the ability of AT1-receptor blockade to enhance natri-
uretic responses to extracellular ﬂuid volume expansion does not
appear to extend to the natriuretic response to plasma volume
expansion.
Compensatory responses to hypovolemia act to blunt the blood
pressure lowering effects of reductions in extracellular ﬂuid vol-
ume and/or blood volume (Evans et al., 2001). We examined the
ability of candesartan to blunt these compensatory responses after
mild hemorrhage. Candesartan treatment enhanced the depres-
sor response to hemorrhage, both by limiting the increase in TPR
and augmenting the fall in CO induced by blood loss. Further-
more, neither GFR nor sodium excretion could be maintained at
their control levels after hemorrhage in candesartan-treated rab-
bits. These observations likely reﬂect the important role of the
RAS in autoregulation of GFR (Hall et al., 1977; Evans et al.,
2010). Our observations are largely consistent with those of previ-
ous studies. For example, in conscious dogs, Francis et al. (2004)
found that losartan treatment exaggerated the reductions in MAP
and led to reduced GFR during hemorrhage. At ﬁrst sight our
data may seem to conﬂict with those of Courneya and Korner
(1991), who detected no effect of combined angiotensin convert-
ing enzyme inhibition and vasopressin V1-receptor antagonism
on the acute circulatory response to hemorrhage in conscious
rabbits. However, they did ﬁnd that this treatment attenuated
the recovery of MAP after hemorrhage, a situation analogous to
our current experimental protocol in which hemodynamic and
renal functionwere assessed across 20minperiods following blood
removal.
Our ﬁndings with regard to the effects of candesartan on
responses of RVR to hemorrhage deserve some comment. RVR
rose during hemorrhage after vehicle treatment, as has been
observed previously in conscious rabbits (Courneya and Korner,
Table 2 | Outcomes of two-way repeated measures analysis of variance for data shown in Figures 2, 3, and 5–8.
Variable Hypoxia (Figures 1–3) Plasma volume expansion (Figures 4–6) Hemorrhage (Figures 7 and 8)
Treatment Time Interaction Treatment Time Interaction Treatment Time Interaction
MAP 0.003 0.23 0.51 0.36 0.32 0.28 0.001 0.001 0.001
HR 0.17 0.001 0.09 0.94 0.28 0.39 0.57 <0.001 0.55
CO 0.40 0.12 0.22 0.83 <0.001 0.36 0.77 <0.001 0.01
RBF 0.003 0.14 0.57 0.03 0.004 0.85 0.04 0.06 0.20
TPR 0.05 0.06 0.14 0.68 <0.001 0.45 0.10 0.05 0.12
RVR 0.02 0.09 0.38 0.01 0.03 0.16 0.03 0.25 0.33
GFR 0.06 0.03 0.62 0.15 0.04 0.29 0.34 0.36 0.16
UNa+V 0.01 0.09 0.09 0.09 0.02 0.23 0.73 0.09 0.64
FENa+ 0.005 0.32 0.12 0.86 0.01 0.73 0.43 0.07 0.69
P values were conservatively adjusted, to account for compound asymmetry, using the Greenhouse–Geisser correction (Ludbrook, 1994). MAP, mean arterial pres-
sure; HR, heart rate; CO, cardiac output; RBF, renal blood ﬂow;TPR, total peripheral resistance; RVR, renal vascular resistance; GFR, glomerular ﬁltration rate; UNa+V,
sodium excretion; FENa+, the fractional excretion of sodium. Degrees of freedom (df) for “treatment” are 1 and 6 for all variables except RBF and RVR (1 and 3). For
hypoxia, degrees of freedom for “time” and the “treatment(time interaction” are 2 and 12 except for RBF and RVR (2 and 6). For hemorrhage, degrees of freedom
for time and the treatment(time interaction are 3 and 18 except for RBF and RVR (3 and 9). For plasma volume expansion, degrees of freedom for time and the
treatment(time interaction are 4 and 24 except for RBF and RVR (4 and 16). P values≤0.05 are in bold font.
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1991; Malpas et al., 1998). This response has been attributed pre-
dominantly to the inﬂuence of increased renal sympathetic nerve
activity, since it was abolished by total autonomic blockade or
sinoaortic baroreceptor denervation (Courneya andKorner, 1991)
and blunted by prior renal denervation (Malpas et al., 1998).
Furthermore, it was little affected by combined blockade of the
RAS (angiotensin converting enzyme inhibition) and vasopressin
V1-receptors (Courneya and Korner, 1991). Yet in our current
study RVR did not increase signiﬁcantly during hemorrhage after
candesartan treatment, raising the possibility of some role for
angiotensin II in the renal vasoconstrictor response to hemor-
rhage. However, we were unable to detect a signiﬁcant interaction
between treatment and time in our factorial analysis of these
data (Table 2), so this aspect of our experiment must be inter-
pretedwith care.Nevertheless,our current data support the notion
that the ability of AT1-receptor antagonists to blunt compen-
satory responses to hypovolemia may contribute to the efﬁcacy
of this therapeutic modality for hypertension. It could also be
argued that such an effect could be deleterious for patients on
AT1-receptor antagonist therapy who are subjected to unexpected
blood loss.
A major strength of our experimental approach in the cur-
rent study was the use of a within-animal design. But important
limitations must be acknowledged. Firstly, because we adminis-
tered candesartan systemically, we could not determine the rela-
tive contributions of peripheral and central AT1-receptors to the
effects we observed. Candesartan can cross the blood brain barrier
(Nishimura et al., 2000), so both peripheral and central actions
could contribute to its effects on the response to hemorrhage.
However, it seems likely that peripheral effects dominate, since the
peptide angiotensin receptor antagonist saralasin,which is unlikely
to cross the blood brain barrier, augmented the depressor response
to hemorrhage when given intravenously (Spielman et al., 1975).
Nevertheless, the effects of AT1-receptor blockade may be partly
mediated within the central nervous system, since Lee et al. (1995)
demonstrated that intracerebroventricular administration of low
doses of losartan or saralasin can blunt compensatory responses
to hemorrhage, while Mathai et al. (1997) found that intracere-
broventricular losartan reduced the level of blood loss required to
elicit the decompensatory phase of the response to hemorrhage
(Evans et al., 2001). A second limitation of our study was that we
did not obtain any measures of the activity of the SNS, so inter-
pretation of our ﬁndings with respect to autonomic control of the
circulation must be associated with caution. A third limitation of
our current study relates to the variability of ourmeasures of renal
excretory function.As a consequence, the power of our experiment
to detect effects on renal excretory function was not as great as the
power to detect changes in systemic and renal hemodynamics. This
may account for our inability to detect some expected effects, such
as reduced sodium excretion during hypoxia and after hemor-
rhage. Finally, because we studied the acute effects of candesartan
in normotensive animals, our ﬁndings may not be generalizable to
the effects of chronic treatment with AT1-receptor antagonists in
hypertension.
In conclusion, our ﬁndings support a role of the RAS, through
activation of AT1-receptors, in supporting MAP and GFR dur-
ing hypovolemia. In contrast, AT1-receptors appear to play lit-
tle role in mediating the renal vasoconstriction, hypoﬁltration,
and antinatriuresis accompanying hypoxia, or the systemic and
renal vasodilatation and natriuresis accompanying plasma volume
expansion.
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